, /PRNewswire/ — Sen-Jam Pharmaceutical, a leader in innovative solutions targeting inflammation and metabolic health, proudly announces a financial and strategic investment from 5 Horizons Capital. Horizon, as the lead investor for the Phase 2 clinical trial of SJP-001, Sen-Jam’s flagship therapeutic, is paving the way for innovation in collaboration with Novotech, a global full-service clinical Contract Research Organization (CRO), while actively seeking follow-on investments to further accelerate this groundbreaking initiative.
The SJP-001 clinical trial, which recently received ethics approval in Australia, is designed to evaluate the therapeutic’s efficacy in mitigating inflammation and promoting metabolic health, specifically targeting relief from dietary and alcohol-induced overindulgence. With the support of 5 Horizons Capital, Sen-Jam is poised to execute a robust trial strategy in collaboration with Novotech, renowned for its expertise in early-phase clinical trials.
Jim Iversen, Co-Founder and CEO of Sen-Jam Pharmaceutical, stated, “We are thrilled to welcome 5 Horizons Capital as a financial and …